Antihipertansif Tedavide Kalp Hızı:Dikkate Alınmalı Mı?

ÖzKalp hızı kardiyovasküler (KV) olaylar ve total mortalite için bir risk faktörüdür. Genel popülasyonda kalp hızı kan basıncı ile ilişkili bulunmuştur ve en yüksek kalp hızları orta-ciddi hipertansiyonu bulunan hastalarda saptanmıştır. Öte yandan, kalp hızının KVolaylar için bir risk faktörü olduğu aşikardır. Fakat, yüksek riskli hipertansiyonda bu risAbstractHeart rate is a risk factor for cardiovascular (CV) events and total mortality. In ge-neral population, heart rate was associated with blood pressure and highest heart rateswere found in patients with moderate-severe hypertension. On the other hand it is ob-vious that heart rate is a risk factor for CV events. However, it is not clear that this riskis still applicable in hypertensive patients with high risk and this should be clarified inhypertension treatment guidelines.kin hâlâ geçerli olup olmadığı açık değildir ve hipertansiyon kılavuzlarının taşikardiyigüçlü bir KV risk faktörü olarak tanımlayıp tanımlamayacağı netleştirilmelidir.

Anahtar Kelimeler:

Taşikardi, hipertansiyon

Heart Rate in Antihypertensive Treatment: Should not be Considered?

AbstractHeart rate is a risk factor for cardiovascular (CV) events and total mortality. In general population, heart rate was associated with blood pressure and highest heart rateswere found in patients with moderatesevere hypertension. On the other hand it is obvious that heart rate is a risk factor for CV events. However, it is not clear that this riskis still applicable in hypertensive patients with high risk and this should be clarified inhypertension treatment guidelines.

Keywords:

Tachycardia, hypertension,

PDF

___

Kaynaklar 1.Factors of risk in the development of coronary heart disease--six yearfollow-up experience. The Framingham Study. KANNEL WB, DAW-BER TR, KAGAN A, REVOTSKIE N, STOKES J 3rd. Ann Intern Med.1961 Jul;55:33-50. 2.Dyer AR, Persky V, Stamler J, Paul O, Shekelle RB, Berkson DM,Lepper M, Schoenberger JA, Lindberg HA. Heart rate as a prognos-tic factor for coronary heart disease and mortality: findings in threeChicago epidemiologic studies. Am J Epidemiol. 1980;112:736-749 3.Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart di-sease, and death: the NHANES I epidemiologic follow-up study. AmHeart J. 1991;121:172-177. 4.Palatini P. Role of elevated heart rate in the development of cardio-vascular disease in hypertension. Hypertension 2011;58:745-50. 5.Palatini P, Dorigatti F, Zaetta V, Mormino P, Mazzer A, Bortolaz-zi A, D'Este D, Pegoraro F, Milani L, Mos L, Group HS. Heart rateas a predictor of development of sustained hypertension in subjectsscreened for stage 1 hypertension: the HARVEST Study. Journal ofHypertension 2006;24:1873-80 6.Morcet JF, Safar M, Thomas F, Guize L, Benetos A. Associations bet-ween heart rate and other risk factors in a large French populati-on. Journal of Hypertension 1999;17:1671-76. 7.Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlof B, Edelman JM,Devereux RB. All-cause and cardiovascular mortality in relation tochanging heart rate during treatment of hypertensive patients withelectrocardiographic left ventricular hypertrophy. Eur Heart J2010;31:2271-79 . 8.Rationaleanddesignof the International Verapamil SR/TrandolaprilStudy (INVEST): an Internet-based randomized trial in coronary ar-tery disease patients with hypertension. Pepine CJ, Handberg-Thur-mond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zel-lig P. J Am Coll Cardiol. 1998 Nov;32(5):1228-37. 9-.Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, CaulfieldM, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, NieminenM, O'Brien E, Ostergren J, Pocock S; ASCOT Investigators. Lancet.2005 Sep 10-16;366(9489):907-13. 10.Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnesGT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zap-pe D, Majahalme S, Jamerson K, Koylan N. Usefulness of heart rateto predict cardiac events in treated patients with high-risk systemichypertension. The Am J Cardiol 2012;109:685-92